(Q41676847)

6 October 2017

1 reference

title

Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension (English)

1 reference

6 October 2017

1 reference

1 reference

2

A Markham

0 references

author name string

J C Gillis

series ordinal

1

1 reference

PubMed ID

9421695

6 October 2017

A Markham

series ordinal

2

1 reference

6 October 2017

1 December 1997

1 reference

6 October 2017

1 reference

6 October 2017

54

1 reference

6 October 2017

6

1 reference

6 October 2017

885-902

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199754060-00007

6 October 2017

0 references

cites work

Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro

1 reference

12 December 2020

Modulation of the renin-angiotensin-aldosterone system and cough.

1 reference

12 December 2020

Calcium antagonists and ACE inhibitors. Effect on endothelium and vascular smooth muscle

1 reference

12 December 2020

A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension.

1 reference

12 December 2020

Angiotensin II receptor subtypes: selective antagonists and functional correlates

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects

1 reference

12 December 2020

The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs

1 reference

12 December 2020

Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men

1 reference

12 December 2020

The 1996 report of a World Health Organization expert committee on hypertension control

1 reference

12 December 2020

Biotransformation of irbesartan in man

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis

1 reference

12 December 2020

Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review

1 reference

12 December 2020

Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist

1 reference

12 December 2020

Early and late haemodynamic and morphological effects of angiotensin II subtype 1 receptor blockade during genetic hypertension development

1 reference

12 December 2020

Summary of 1993 World Health Organisation-International Society of Hypertension guidelines for the management of mild hypertension. Subcommittee of WHO/ISH Mild Hypertension Liaison committee

1 reference

12 December 2020

Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension

1 reference

12 December 2020

Impact of antihypertensive therapy on progression of experimental renal disease

1 reference

12 December 2020

Angiotensin II receptor antagonists versus angiotensin converting enzyme inhibitors: effects on renal function.

1 reference

12 December 2020

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

1 reference

12 December 2020

The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis

1 reference

12 December 2020

Angiotensin II receptors and angiotensin II receptor antagonists.

1 reference

12 December 2020

Effects of angiotensin receptor antagonists in heart failure: clinical and experimental aspects

1 reference

12 December 2020

Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension

1 reference

12 December 2020

ACE inhibitors and the kidney. A risk-benefit assessment

1 reference

12 December 2020

Current drug treatment and treatment patterns with antihypertensive drugs

1 reference

12 December 2020

The renin-angiotensin system and vascular hypertrophy

1 reference

12 December 2020

Renal circulation and blockade of the renin-angiotensin system. Is angiotensin-converting enzyme inhibition the last word?

1 reference

12 December 2020

Choice of initial therapy for hypertension

1 reference

12 December 2020

1 reference

12 December 2020

The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)

1 reference

12 December 2020

Novel drugs and current therapeutic approaches in the treatment of heart failure

1 reference

12 December 2020

Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators

1 reference

12 December 2020

Angiotensin II receptor blockers. A new class of antihypertensive drugs.

1 reference

12 December 2020

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension

1 reference

12 December 2020

Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects

1 reference

12 December 2020

24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring

1 reference

12 December 2020

Trough/peak ratios for antihypertensive agents. The issues in perspective

1 reference

12 December 2020

Use of angiotensin II antagonists in human heart failure: function of the subtype 1 receptor.

1 reference

12 December 2020

Characterization of cardiac angiotensin AT1 receptors by [3H]SR 47436

1 reference

12 December 2020

The effects of age and gender on the pharmacokinetics of irbesartan

1 reference

12 December 2020

10.2165/00003495-199754060-00007

Identifiers

DOI

1 reference

PubMed ID

9421695

Dimensions Publication ID

6 October 2017

0 references

1 reference

PubMed ID

9421695